First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

Abstract Background Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-associated vasculitis (AAV) and as off-la...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Francesca Faustini, Nicky Dunn, Nastya Kharlamova, Malin Ryner, Annette Bruchfeld, Vivianne Malmström, Anna Fogdell-Hahn, Iva Gunnarsson
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	BMC 2021-08-01
Cyfres:	Arthritis Research & Therapy
Pynciau:	Rituximab Anti-drug antibodies (ADA) Systemic lupus erythematosus ANCA-associated vasculitis Disease activity B cell counts
Mynediad Ar-lein:	https://doi.org/10.1186/s13075-021-02589-6
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!